2026 Global: Coagulation Factor Xi Market -Competitive Review (2032) report
Description
The 2026 Global: Coagulation Factor Xi Market-Competitive Review (2032) report features the global market size and projected growth/decline data for the period 2021 and 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Leading the coagulation Factor XI market are Grifols S.A. (HQ: Barcelona, Spain), CSL Behring (HQ: King of Prussia, United States), Octapharma AG (HQ: Lachen, Switzerland), and Kedrion Biopharma, Inc. (HQ: Fort Lee, United States). These companies control substantial portions of FXI concentrates and related plasma-derived products used in treatment of Factor XI deficiency and bleeding disorders. Grifols, a Spanish multinational, leverages integrated plasma collection, fractionation, and distribution networks to supply Factor XI through its global portfolio. CSL Behring, part of the CSL Limited group, operates extensive plasma programs and manufacturing facilities to ensure supply continuity across North America, Europe, and Asia. Octapharma, headquartered in Switzerland, offers multiple coagulation factors, with Factor XI products distributed internationally through its network. Kedrion Biopharma, headquartered in the United States, develops and licenses FXI-containing plasma products for hospital and specialty pharmacies, with a focus on high-purity fractions and rigorous safety standards. Market dynamics remain evolving.
Expanding FXI activity across Europe and beyond, LFB Group (HQ: Paris, France), Sanquin Plasma Products (HQ: Amsterdam, Netherlands), Biotest AG (HQ: Dreieich, Germany), and Bio Products Laboratory (HQ: Slough, United Kingdom) play pivotal roles. LFB’s European footprint encompasses fractionation capabilities, quality-controlled plasma pools, and regulatory-compliant distribution that help sustain FXI availability for clinical use. Sanquin, as a national blood- and plasma-derived products organization, integrates donation, fractionation, and clinical collaboration to support FXI treatment programs while ensuring patient safety. Biotest maintains diversified Plasma Fractionation operations with facilities in Germany and abroad, emphasizing purity, consistent potency, and logistical reliability for coagulation therapies. BPL, with operations in the United Kingdom, contributes to the FXI supply chain through specialized plasma-derived products and stringent quality management systems that align with international standards. Together, these firms complement the larger players by expanding access, driving process innovations, and reinforcing resilience in the FXI market amid supply fluctuations.
Beyond established Western suppliers, East Asia hosts emerging FXI players such as Green Cross Corporation (HQ: Seoul, South Korea) and Kamada Ltd. (HQ: Rehovot, Israel). These firms broaden regional access to Factor XI therapies through localized plasma collection networks, process optimization, and regulatory alignment that complement long-standing manufacturers. Green Cross, as a major Korean biopharma and blood products company, leverages its domestic base to support FXI-related treatment programs, while Kamada pursues specialized manufacturing capabilities and global distribution partnerships to extend reach. Innovation in FXI product development—whether plasma-derived concentrates, recombinant variants, or antibody-based inhibitors—depends on cross-border collaboration, quality assurance, and rigorous pharmacovigilance. The competitive landscape remains dynamic as regulatory expectations tighten, supply chains diversify, and clinical evidence evolves. Collectively, ten companies described here represent an ecosystem that advances patient access to Factor XI therapies and supports risk-adjusted outcomes through standardized manufacturing, robust supply chain management, and adherence to international quality standards.
Leading the coagulation Factor XI market are Grifols S.A. (HQ: Barcelona, Spain), CSL Behring (HQ: King of Prussia, United States), Octapharma AG (HQ: Lachen, Switzerland), and Kedrion Biopharma, Inc. (HQ: Fort Lee, United States). These companies control substantial portions of FXI concentrates and related plasma-derived products used in treatment of Factor XI deficiency and bleeding disorders. Grifols, a Spanish multinational, leverages integrated plasma collection, fractionation, and distribution networks to supply Factor XI through its global portfolio. CSL Behring, part of the CSL Limited group, operates extensive plasma programs and manufacturing facilities to ensure supply continuity across North America, Europe, and Asia. Octapharma, headquartered in Switzerland, offers multiple coagulation factors, with Factor XI products distributed internationally through its network. Kedrion Biopharma, headquartered in the United States, develops and licenses FXI-containing plasma products for hospital and specialty pharmacies, with a focus on high-purity fractions and rigorous safety standards. Market dynamics remain evolving.
Expanding FXI activity across Europe and beyond, LFB Group (HQ: Paris, France), Sanquin Plasma Products (HQ: Amsterdam, Netherlands), Biotest AG (HQ: Dreieich, Germany), and Bio Products Laboratory (HQ: Slough, United Kingdom) play pivotal roles. LFB’s European footprint encompasses fractionation capabilities, quality-controlled plasma pools, and regulatory-compliant distribution that help sustain FXI availability for clinical use. Sanquin, as a national blood- and plasma-derived products organization, integrates donation, fractionation, and clinical collaboration to support FXI treatment programs while ensuring patient safety. Biotest maintains diversified Plasma Fractionation operations with facilities in Germany and abroad, emphasizing purity, consistent potency, and logistical reliability for coagulation therapies. BPL, with operations in the United Kingdom, contributes to the FXI supply chain through specialized plasma-derived products and stringent quality management systems that align with international standards. Together, these firms complement the larger players by expanding access, driving process innovations, and reinforcing resilience in the FXI market amid supply fluctuations.
Beyond established Western suppliers, East Asia hosts emerging FXI players such as Green Cross Corporation (HQ: Seoul, South Korea) and Kamada Ltd. (HQ: Rehovot, Israel). These firms broaden regional access to Factor XI therapies through localized plasma collection networks, process optimization, and regulatory alignment that complement long-standing manufacturers. Green Cross, as a major Korean biopharma and blood products company, leverages its domestic base to support FXI-related treatment programs, while Kamada pursues specialized manufacturing capabilities and global distribution partnerships to extend reach. Innovation in FXI product development—whether plasma-derived concentrates, recombinant variants, or antibody-based inhibitors—depends on cross-border collaboration, quality assurance, and rigorous pharmacovigilance. The competitive landscape remains dynamic as regulatory expectations tighten, supply chains diversify, and clinical evidence evolves. Collectively, ten companies described here represent an ecosystem that advances patient access to Factor XI therapies and supports risk-adjusted outcomes through standardized manufacturing, robust supply chain management, and adherence to international quality standards.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
